Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
22-03-2022
EUIPO sides with Takeda in trademark appeal
28-11-2018
AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug
29-08-2017
Jonathan Weiss / Shutterstock.com
Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, Par Pharmaceuticals, US District Court for the District of Massachusetts, FWK Holdings, Amitza
